MedicaidCoverageMedium impact

Newsletter Vol. 11, No. 34

Q: Who is affected by this change?

This affects New Jersey Medicaid Endocrinology, Rheumatology, Gastroenterology, Family Medicine, Internal Medicine providers in NJ on Medicaid plans.

New Jersey Medicaid·NJ · Endocrinology, Rheumatology, Gastroenterology +2 more·Provider Notice

Effective date

Not stated

We identified it

Jun 20, 2026

Days to comply

—

Summary

This provider notice contains information about the use of Bisphosphonates and Acid-Related Drugs (ARDs), likely covering coverage criteria, prior authorization requirements, or billing guidelines for these medication categories used to treat osteoporosis and acid-related conditions.

Action Required

Action needed

Immediately: Review Newsletter Vol. 11, No. 34 from NJ MMIS for specific guidance on Bisphosphonates and Acid-Related Drugs. Billing team should download the full document from the provided URL to determine exact requirements for coverage criteria, prior authorization needs, or documentation requirements for these medications.

Related policy hubs

New Jersey Medicaid policies NJ policy changes Endocrinology Rheumatology Gastroenterology Family Medicine Internal Medicine